Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

WASHINGTON -- Induction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy for patients with moderately to severely active Crohn's disease, topping both ...

Predictive Factors Shape Guselkumab Response in Psoriasis About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20 ...

The "Hidradenitis Suppurativa Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to ...